COCHRANE CORNER
Is methotrexate effective and safe in patients with psoriatic arthritis? A Cochrane Review summary with commentary
Frane Grubišić,
Corresponding Author
Frane Grubišić
Department of Rheumatology, Physical Medicine and Rehabilitation, School of Medicine, University of Zagreb, Zagreb, Croatia
Referral Center for the Spondyloarthropathy, Ministry of Health of the Republic of Croatia, University Hospital Center “Sestre Milosrdnice”, Zagreb, Croatia
Correspondence
Frane Grubišić, Department of Rheumatology, Physical Medicine and Rehabilitation, School of Medicine University of Zagreb, Zagreb, Croatia.
Email: [email protected]
Search for more papers by this author
Frane Grubišić,
Corresponding Author
Frane Grubišić
Department of Rheumatology, Physical Medicine and Rehabilitation, School of Medicine, University of Zagreb, Zagreb, Croatia
Referral Center for the Spondyloarthropathy, Ministry of Health of the Republic of Croatia, University Hospital Center “Sestre Milosrdnice”, Zagreb, Croatia
Correspondence
Frane Grubišić, Department of Rheumatology, Physical Medicine and Rehabilitation, School of Medicine University of Zagreb, Zagreb, Croatia.
Email: [email protected]
Search for more papers by this author
First published: 22 October 2020
No abstract is available for this article.
CONFLICT OF INTEREST
The author declares no conflicts of interest.
REFERENCES
- 1Wilsdon TD, Whittle SL, Thynne TRJ, Mangoni AA. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019;( 1): CD012722. https://doi.org/10.1002/14651858.CD012722.pub2
- 2Stolwijk C, Van Onna M, Boonen A, Van Tubergen A. The global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res. 2016; 68(9): 1320-1331.
- 3Duarte GV, Faillace C, Freire de Carvalho J. Psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012; 26(1): 147-156.
- 4Coates LC, Helliwell PS. Psoariatic arthritis: state of the art review. Clin Med. 2017; 17(1): 65-70.
- 5Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016; 75: 499-510.
- 6Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016; 68: 1060-1071.
- 7Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res. 2019; 71(1): 2-29.
- 8Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019; 8:1665.
- 9Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology. 2012; 51(8): 1368-1377.
- 10Soriano ER. Management of psoriatic arthritis: traditional disease-modifying rheumatic agents and targeted small molecules. Rheum Dis Clin North Am. 2015; 41(4): 711-722.
- 11Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014; 73(8): 1549-1551.
